Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

    ... leukemia (AML) unlikely to benefit from cytotoxic chemotherapy . Switching hypomethylating agents after treatment failure is ...

    Research Article last updated 10/02/2014 - 10:13am.

  2. Update on the pharmacotherapy for myelodysplastic syndromes

    ... relied upon supportive care and intensive chemotherapy . The last decade has seen many scientific and therapeutic ...

    Research Article last updated 08/21/2014 - 9:23am.

  3. Myelodysplastic syndromes

    ... in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most ...

    Research Article last updated 04/16/2014 - 12:04pm.

  4. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... Due to their lower toxicity compared to conventional chemotherapy , hypomethylating agents are often a safe and feasible ... may play a role in epigenetic "priming" before conventional chemotherapy. This review summarizes the results of clinical trials and ...

    Research Article last updated 11/05/2012 - 9:34am.

  5. Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System.

    ... care without specific therapy, with AML-like chemotherapy , or with other therapy regimens (low-dose chemotherapy, demethylating agents, immune modulating agents, valproic acid, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

    ... myeloproliferative disorders (MPD). Giving low doses of chemotherapy , such as fludarabine phosphate, and total-body irradiation ... transplant helps stop the growth of cancer cells. Giving chemotherapy or radiation therapy before or after transplant also stops the ...

    Clinical Trial last updated 04/28/2016 - 2:45pm.

  7. Transplantation strategies for the management of patients with myelodysplastic syndromes.

    ... are almost equal with the results obtained by intensive chemotherapy alone. Failure was due primarily to TRM in patients with ... the procedure. Autologous SCT after successful induction chemotherapy may increase the proportion of long-term survivors, thus ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. First-in Human Clinical Transplant Trial for Severe Aplastic Anemia

    ... T cells still present and then about 4 days later giving chemotherapy to kill these T cells. The approach we studied involved using ... half- matched transplant, including the lack of any need for chemotherapy after a haplo transplant. With those types of transplants, there ...

    Interview last updated 10/04/2017 - 1:36pm.

  9. How we treat higher-risk myelodysplastic syndromes

    ... hypomethylating agent therapy, induction chemotherapy or a clinical trial should be considered to prevent ...

    Research Article last updated 01/08/2014 - 8:57am.

  10. Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study

    ... received disease-modifying therapies (DMT) that included chemotherapy (CHT) for 65 patients, allogeneic stem-cell transplantation ...

    Research Article last updated 04/02/2013 - 7:59am.